NZ755301A - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
NZ755301A
NZ755301A NZ755301A NZ75530118A NZ755301A NZ 755301 A NZ755301 A NZ 755301A NZ 755301 A NZ755301 A NZ 755301A NZ 75530118 A NZ75530118 A NZ 75530118A NZ 755301 A NZ755301 A NZ 755301A
Authority
NZ
New Zealand
Prior art keywords
cancer treatment
cancer
treatment
erdafitinib
provides
Prior art date
Application number
NZ755301A
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Anne Elizabeth O’Hagan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ755301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to NZ796822A priority Critical patent/NZ796822A/en
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of NZ755301A publication Critical patent/NZ755301A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
NZ755301A 2017-02-06 2018-02-02 Cancer treatment NZ755301A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ796822A NZ796822A (en) 2017-02-06 2018-02-02 Cancer treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
NZ755301A true NZ755301A (en) 2025-12-19

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ755301A NZ755301A (en) 2017-02-06 2018-02-02 Cancer treatment
NZ796822A NZ796822A (en) 2017-02-06 2018-02-02 Cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ796822A NZ796822A (en) 2017-02-06 2018-02-02 Cancer treatment

Country Status (26)

Country Link
US (2) US11077106B2 (https=)
EP (2) EP4286005A3 (https=)
JP (3) JP2020505425A (https=)
KR (2) KR20250069693A (https=)
CN (1) CN110198716A (https=)
AU (2) AU2018216969B2 (https=)
BR (1) BR112019016043A2 (https=)
CA (1) CA3049737A1 (https=)
DK (1) DK3576740T3 (https=)
ES (1) ES2953005T3 (https=)
FI (1) FI3576740T3 (https=)
HR (1) HRP20230697T1 (https=)
HU (1) HUE062453T2 (https=)
IL (1) IL268463A (https=)
JO (1) JOP20190190B1 (https=)
LT (1) LT3576740T (https=)
MX (2) MX2019009304A (https=)
NZ (2) NZ755301A (https=)
PH (1) PH12019501885A1 (https=)
PL (1) PL3576740T3 (https=)
RS (1) RS64778B1 (https=)
SG (2) SG10202105110VA (https=)
SI (1) SI3576740T1 (https=)
SM (1) SMT202300233T1 (https=)
TW (1) TWI874925B (https=)
UA (1) UA126336C2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
EP3923942A1 (en) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Cancer treatment
PH12021552342A1 (en) * 2019-03-29 2022-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése

Also Published As

Publication number Publication date
DK3576740T3 (da) 2023-07-24
TW202402290A (zh) 2024-01-16
JP2025024064A (ja) 2025-02-19
AU2024201871B2 (en) 2026-02-26
US20200022976A1 (en) 2020-01-23
HRP20230697T1 (hr) 2023-10-13
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
ES2953005T3 (es) 2023-11-07
LT3576740T (lt) 2023-08-10
IL268463A (en) 2019-09-26
KR20250069693A (ko) 2025-05-19
EP4286005A3 (en) 2024-03-06
EP4286005A2 (en) 2023-12-06
MX2019009304A (es) 2019-09-19
JP7668777B2 (ja) 2025-04-25
SMT202300233T1 (it) 2023-09-06
US11077106B2 (en) 2021-08-03
TWI874925B (zh) 2025-03-01
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
CA3049737A1 (en) 2018-08-09
MX2022007955A (es) 2022-07-27
CN110198716A (zh) 2019-09-03
AU2018216969A1 (en) 2019-07-25
HUE062453T2 (hu) 2023-11-28
JOP20190190A1 (ar) 2019-08-04
KR20190110581A (ko) 2019-09-30
JP2020505425A (ja) 2020-02-20
BR112019016043A2 (pt) 2020-03-31
SG10202105110VA (en) 2021-06-29
RS64778B1 (sr) 2023-11-30
EP3576740B1 (en) 2023-06-14
EP3576740A1 (en) 2019-12-11
PL3576740T3 (pl) 2023-09-11
PH12019501885A1 (en) 2020-06-29
FI3576740T3 (fi) 2023-08-31
JOP20190190B1 (ar) 2024-04-18
NZ796822A (en) 2025-12-19
AU2018216969B2 (en) 2024-04-11
AU2024201871A1 (en) 2024-04-11
SI3576740T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP3641770A4 (en) CANCER TREATMENT METHODS
PH12017501999A1 (en) K-ras modulators
EA201991818A1 (ru) Лечение рака
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
TW201613587A (en) Medical treatments based on anamorelin
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12017501864A1 (en) Compositions and methods for treating autism
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2018000694A (es) Tratamiento del prurito.
PH12021551949A1 (en) Cancer treatment
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
MX2017003728A (es) Sistema mejorador de sabor.
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3674812, STUYCKENS, KIM, C/O JANSSEN PHARMACEUTICA NVTURNHOUTSEWEG 302340 BEERSE, , BE; 3674813, PEREZ RUIXO, JUAN, JOSE, C/O JANSSEN-CILAG, S.A., EDIFICIO JOHNSON + JOHNSON,PASEO DE LAS DOCE ESTRELLAS,5-7, 5AO PLANTA, CAMPO DE LAS NACIONES28042 MADRID, , ES; 3674814, DE PORRE, PETER, MARIE, Z., C/O JANSSEN PHARMACEUTICA NVTURNHOUTSEWEG 302340 BEERSE, , BE; 3674815, AVADHANI, ANJALI, NARAYAN, C/O JANSSEN PHARMACEUTICALS INC., SPRINGHOUSE CAMPUS 1400 MCKEAN ROAD SPRINGHOUSE , PENNSYLVANIA 19477, US; 3674816, LORIOT, YOHANN, C/O GUSTAVE ROUSSY114, RUE A DOUARD-VAILLANT94805 VILLEJUIF CEDEX, , FR; 3674817, SIEFKER-RADTKE, ARLENE, O., C/O JANSSEN PHARMACEUTICA

Effective date: 20240311

PSEA Patent sealed